Our commitment to transforming cancer treatment extends to rigorous immunotherapy research. At OncoVanta Therapeutics, we conduct extensive studies that explore the potential of TCR-T cell therapies in targeting mutant TP53 cancers. This research not only informs our therapy development but also contributes to the broader scientific community's understanding of immunotherapy. By investing in innovative research, we strive to uncover new methodologies and strategies that enhance therapeutic efficacy and patient safety. Our goal is to lead the way in developing breakthroughs that can significantly improve outcomes for cancer patients.